A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC) - Regional Cancer Care Associates LLC

Clinical Trials

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung
Locations
East Brunswick
Sponsor
Clovis
Protocol Number
CO-1686-008 (Tiger X)
Cancer Diagnosis
Non-small cell lung cancer
To Learn More Call
201-510-0910